After attending Johns Hopkins University School of Medicine, Kenneth Anderson, MD, completed his residency at the Johns Hopkins School of Medicine, and subsequently trained in hematology, medical oncology, and tumor immunology at the Dana-Farber Cancer Institute.
Prof. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, and Program Director Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics. He is a Doris Duke Distinguished Clinical Research Professor and has been the recipient of many awards during his career. These include the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award, the American Cancer Society Medal of Honor, and the Samuel Waxman Research Foundation David Workman Memorial Award.
Speaking on translational research in multiple myeloma
Prof. Anderson has dedicated four decades of research into multiple myeloma: developing myeloma models to understand its mechanisms of growth and drug resistance, both genetically and molecularly, identifying novel therapeutic targets, and designing new treatments. His work has identified targets for, and led to the development of, monoclonal antibodies, immunomodulators and proteasome inhibitors, all ultimately gaining FDA approval and transforming myeloma treatment. He continues to investigate the microenvironment, genetics and immune system in MM in order to identify next-generation targeted treatments.